Cas No.: | 2095128-20-2 |
Chemical Name: | Unii-fko8A7AD54 |
Synonyms: | FKO8A7AD54;Bocidelpar;Bocidelpar [USAN];ASP0367;WHO 11924;(3R)-3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoic acid;Hexanoic acid, 3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)-, (3R)-;Unii-fko8A7AD54 |
SMILES: | FC(C1C=CC(=CC=1)C1=NC=C(C)N1CC1C=CC=CC=1OCCC[C@@H](C)CC(=O)O)(F)F |
Formula: | C25H27F3N2O3 |
M.Wt: | 460.488697290421 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Bocidelpar is a modulator of peroxisome proliferator-activated receptor delta (PPAR-δ). Bocidelpar improves mitochondrial biogenesis and function in Duchenne Muscular Dystrophy (DMD) muscle cells (extracted from patent WO2017062468A1, compound 2b)[1]. |
Target: | PPAR-δ[1] |
References: | [1]. Michael Downes, et al. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof. Patent WO2017062468A1. |